ABSTRACT BACKGROUND Costs and uncertainty about the benefits of nonstatin therapies limit their use.
New evidence has emerged since the ACC pathway was completed that suggests how to determine quantitation of net benefit. We and others have recently shown that quantitation of the absolute benefit from an added therapy can inform clinical decision-making (4) (5) (6) . Absolute risk reduction (ARR) from added therapy can be quantified as the number needed to treat (NNT) to prevent the first event in a given time horizon, which then allows comparison to the number that would need to be treated to cause 1 adverse event (number needed to harm [NNH] ). Consideration of NNT and NNH can be used to inform the clinicianpatient discussion and is an important step toward supporting personalized medicine. NNT and NNH can also be used to define patient groups using a combination of absolute risk and LDL-C thresholds likely to benefit from the addition of a nonstatin therapy. Because no trial specifically enrolled patients with familial hypercholesterolemia (FH), we performed a systematic review of observational studies. We were unable to identify any publications reporting 10-year ASCVD rates in statin-treated FH patients, although 2 were identified subsequent to the completion of the search (8, 9) . We therefore undertook an analysis of the national cascade screening program conducted in the Netherlands from 1994 to 2010, which has been described in detail previously (Online Appendix C) (10, 11) .
METHODS

RELATIVE RISK REDUCTION WITH NONSTATIN
THERAPY. The ACC pathway identified ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and bile acid sequestrants as nonstatin options for additional LDL-C lowering. The magnitude of LDL-C lowering with these nonstatins varies, and only ezetimibe has been shown to clearly reduce ASCVD events when added to background statin therapy (2, 12) . Cholestyramine has been shown to reduce cardiovascular events in men with hypercholesterolemia, but no cardiovascular outcomes trials have been performed for bile acid sequestrants in the setting of background statin therapy (13) . The ACC pathway did not recommend niacin or fibrates for additional LDL-C lowering. These treatments modestly reduce LDL-C <10%, and do not appear to reduce ASCVD risk when added to background statin therapy; niacin substantially increases adverse events (2, 14) .
The relative reduction in cardiovascular events for statins, ezetimibe, and possibly PCSK9 monoclonal antibodies (mAbs), has been found to be consistent with the relationship described in the CTT (Cholesterol Treatment Trialists) meta-analysis, wherein each 39 mg/dl (1 mmol/l) reduction in LDL-C was associated with a 21% reduction in major cardiovascular events (Figure 1) (3, 12, (15) (16) (17) . Thus, the average relative risk reduction from adding 1 of these LDL-Clowering therapies was considered a linear function of the reduction in LDL-C level on statin therapy and approximated by 0.21Â the mmol/l reduction in LDL-C for this analysis. International Trial) to determine ezetimibe efficacy, a systematic review of PCSK9 mAb trials, and previous systematic reviews of bile acid sequestrants (Online Appendix D) (2, 12, 18, 19) .
ESTIMATION OF NNT AND ADVERSE EVENT RATES.
To estimate the NNT, the magnitude of LDL-C reduction was calculated as a product of the on-statin treated LDL-C level and the average percent LDL-C reduction for 2 nonstatins: ezetimibe and PCSK9 mAbs (Online Appendix D). Adverse event rates were derived from the active arms of these trials. analysis (20) . For simplicity, the 5-year event rates were conservatively estimated as one-half of the lower risk threshold used to define the risk category.
RESULTS
ABSOLUTE RISKS. We identified 6 RCTs from the 2013 ACC/AHA guideline systematic review and MEDLINE search that reported ASCVD events as a primary or secondary outcome (Online Appendix B).
These trials had been graded as fair to good quality by the National Heart, Lung, and Blood Institute criteria developed for their systematic review (7) . From these 6 trials, 16 papers reported ASCVD event rates for subgroups that were used to identify absolute risk levels for the patient risk categories used in the ACC pathway or other patient subgroups on the basis of sex, age, or multivessel ASCVD (Online Appendix B, Online Table B1 ). The large majority of these were post hoc subgroup analyses.
Patients included in the ACC pathway category of "clinical ASCVD with comorbidities" were at very high risk, and largely had a projected 10-year ASCVD risk $30% despite moderate-or high-intensity statin therapy: 26% to 43% for those with ASCVD and dia- Table B1 ) (8) . The ACC pathway also identified patients with ASCVD and elevated lipoprotein (a) levels or recurrent ASCVD events as high risk; however, we were unable to find subgroup analyses that reported event rates for these patient groups (21) .
Patients included in the ACC pathway category of "clinical ASCVD without comorbidities" were high risk, with 10-year ASCVD risks of 20% to 29% on moderate-or high-intensity statin therapy. However, lower 10-year risks were consistently observed among some groups of ASCVD patients without comorbidities who were receiving high-intensity statin therapy (e.g., no diabetes: 16% to 20%; nonsmokers or former smokers: 10% to 26%; and controlled hypertension:
16% to 20%) (Online Appendix B, Online Table B1 ).
Other high-risk patient groups with coronary heart disease included who had undergone coronary artery bypass grafting, those without peripheral arterial dis- Patients included in the ACC pathway category of "primary prevention diabetes with LDL-C <190 mg/dl" had a 10-year ASCVD risk <20% on a moderateintensity statin (Onlline Appendix B, Online Table B1 ).
RELATIVE RISK REDUCTION AND NNTs FOR
NONSTATINS. To compare NNTs, representative LDL-C reductions of 20%, 35%, 50%, and 65% were selected on the basis of average efficacies for ezetimibe, combinations of 2 nonstatins other than a PCSK9 mAb, and PCSK-9 mAbs (Online Appendix D) (12, (16) (17) (18) (19) (22) (23) (24) (25) (26) (27) .
Preliminary data has shown that evolocumab and alirocumab reduced major cardiovascular events over a period of 11 to 18 months in patients with average
baseline LDL-C levels of 120 to 122 mg/dl (16,17). 
Adding Nonstatin Therapy
Representative NNTs for 5 years of treatment for several percent reductions in LDL-C, absolute risk thresholds, and baseline LDL-C levels are provided in Table 1 . Abbreviations as in Table 1 .
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Adding Nonstatin Therapy ance copayments, and whether the additional drug will jeopardize adherence to other evidence-based therapies (1, 3) . A case example is provided in Table 3 .
COST PERSPECTIVE. Currently, the cost of the PCSK9 mAbs precludes widespread use of these drugs in patients who might benefit (20, 29) . The "rule of thumb" categories of patients who are likely to experience an atherosclerotic cardiovascular disease (ASCVD) risk reduction benefit from additional lowdensity lipoprotein cholesterol (LDL-C)-lowering therapy, considering both clinical and cost perspective (assuming no adverse events). mAb ¼ monoclonal antibody; NNT ¼ number needed to treat. J.V. is a 43-yr-old African-American woman who had an LDL-C of 256 mg/dl identified for the first time in a workplace screening. At the follow-up primary care physician visit, she reported that she had been told her cholesterol was high before starting oral contraceptives; however, her good cholesterol was high too, so she only needed to follow a low cholesterol diet, which she does. Her father had an MI at age 39 yrs, and his brother had an MI at age 42 yrs; both were smokers, and cholesterol status was unknown. Her 2 children have never had their cholesterol checked. She is a nonsmoker and is currently taking oral contraceptives. Adding Nonstatin Therapy D E C E M B E R 6 , 2 0 1 6 : 2 4 1 2 -2 1
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